(Q82331363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

title

New approaches to the treatment of osteoporosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

New Approaches to the Treatment of Osteoporosis (English)

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

21 August 2024

author

Barbara Campolina Silva

series ordinal

object named as

Barbara C. Silva

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21054170

21 August 2024

John P. Bilezikian

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21054170

21 August 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21054170

21 August 2024

publication date

1 January 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

full work available at URL

15 January 2020

http://arjournals.annualreviews.org/doi/abs/10.1146/annurev-med-061709-145401

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21054170

https://www.annualreviews.org/doi/pdf/10.1146/annurev-med-061709-145401

21 August 2024

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Annual Review of Medicine

21 August 2024

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

page(s)

307-322

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

15 January 2020

cites work

1 reference

5 June 2022

https://opencitations.net/index/coci/api/v1/citations/10.1007/S00198-006-0172-4

Epidemiology of osteoporosis

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Update in male osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Could strontium ranelate have a synergistic role in the treatment of osteoporosis?

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Transmission of human herpesvirus 8 by blood transfusion

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Impact of osteoporosis treatment adherence on fracture rates in North America and Europe.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

New therapies for osteoporosis: zoledronic acid, bazedoxifene, and denosumab

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Treatment of osteoporosis and prevention of new fractures: role of intravenously administered bisphosphonates

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Zoledronic acid and clinical fractures and mortality after hip fracture

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Atrial fibrillation and bisphosphonate therapy

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Osteonecrosis of the jaw--do bisphosphonates pose a risk?

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Bone turnover 18 months after a single intravenous dose of zoledronic acid.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

The antiresorptive effects of a single dose of zoledronate persist for two years: a randomized, placebo-controlled trial in osteopenic postmenopausal women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Selective estrogen receptor modulators: an update on recent clinical findings

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Lasofoxifene in postmenopausal women with osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Designing the ideal selective estrogen receptor modulator--an achievable goal?

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of arzoxifene on bone mineral density and endometrium in postmenopausal women with normal or low bone mass

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Denosumab in postmenopausal women with low bone mineral density

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMD

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

The long and the short of bone therapy

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Increasing options for the treatment of osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Cathepsin K: a therapeutic target for bone diseases

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Pycnodysostosis: role and regulation of cathepsin K in osteoclast function and human disease

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Drug-induced morphea: report of a case induced by balicatib and review of the literature

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Parathyroid hormone as an anabolic skeletal therapy

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Elongated styloid process and atheroma in panoramic radiography and its relationship with systemic osteoporosis and osteopenia.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effect of prostaglandin F2 alpha on human parathyroid adenomas: evidence for uncoupling of parathyroid hormone secretion and cAMP accumulation

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent.

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

New anabolic therapies in osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Effects of teriparatide retreatment in osteoporotic men and women

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Retreatment with teriparatide one year after the first teriparatide course in patients on continued long-term alendronate

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/beta-catenin signaling

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

A short treatment with an antibody to sclerostin can inhibit bone loss in an ongoing model of colitis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Patients with high-bone-mass phenotype owing to Lrp5-T253I mutation have low plasma levels of serotonin

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis

21 August 2024

1 reference

https://api.crossref.org/works/10.1146/ANNUREV-MED-061709-145401

21 August 2024

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json

15 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21054170%20AND%20SRC:MED&resulttype=core&format=json